Calcifar Plus

Quick links to important sections

Calcifar Plus

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcifar Plus

Property Description
Active ingredient Calcium Hydrogen Phosphate, Colecalciferol (Vitamin D3)
Form Oral (Kaplet/Tablet, Chewable Tablet)
Pharmacological class Multivitamins and Minerals, Supplements and Adjuvant Therapies
Common purpose Prevention and treatment of Calcium and Vitamin D deficiencies
Origin Derived (Formulated combination)

Defining Calcifar Plus: Combination, Class, and Form

Calcifar Plus is a combination medication classified within the Multivitamins and Minerals pharmacological class. It functions as a supplement and adjuvant therapy by providing two essential micronutrients together in a single oral dosage form. It is available as a Kaplet (tablet) or a Chewable Tablet, a distinctive form designed to offer flexibility for individuals who may have difficulty swallowing standard tablets. This structure is a derived product, intentionally combining components to ensure balanced nutritional support.


What is Calcifar Plus Made Of? Active Ingredients and Composition

This preparation utilizes two primary active ingredients: the mineral source Calcium Hydrogen Phosphate and the fat-soluble vitamin Colecalciferol (Vitamin D3). Calcium Hydrogen Phosphate supplies necessary calcium salt and phosphate ions. The formulation specifically includes Colecalciferol because this form of Vitamin D is necessary for the proper absorption of dietary calcium. This dual-component approach is essential, as the vitamin component actively regulates the metabolism and utilization of the mineral source.


What Is the General Purpose of This Combination Supplement?

The general purpose of Calcifar Plus is to support the body's mineral homeostasis by addressing the established physiological requirement for both calcium and Vitamin D3. The preparation is typically used by adults and older individuals as a practical approach to ensure adequate daily intake of these essential nutrients. By supplying the mineral source alongside the compound that enhances its intestinal uptake, the preparation aids in the prevention and treatment of deficiencies in these two components, supporting overall bone strength and systemic health.

Regulatory References

  1. Vitamin D and Calcium absorption

What side effects are possible with Calcifar Plus?

Possible Side Effects and Safety Information

Calcifar Plus has an established safety profile with documented risks based on regulatory agency reviews. The most common adverse reactions (observed in 3% of clinical trial participants) are typically gastrointestinal in nature and include abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, nausea, and musculoskeletal pain.

Serious and Clinically Significant Adverse Reactions

Several serious risks are noted in the regulatory labeling:

  • Upper Gastrointestinal (GI) Irritation: Severe irritation, such as esophagitis, esophageal ulcers, and erosions, can occur. The risk is reduced by strict adherence to proper administration instructions. Caution is advised for those with active upper GI disease.
  • Musculoskeletal Pain: Severe bone, joint, or muscle pain may develop, sometimes requiring discontinuation of the product.
  • Atypical Fractures: Atypical subtrochanteric and diaphyseal femoral fractures have been reported; patients who experience new thigh or groin pain should be medically evaluated.
  • Osteonecrosis of the Jaw (ONJ): ONJ has been reported rarely, typically in the post-marketing setting.
  • Mineral Metabolism: The product is contraindicated in patients with pre-existing hypocalcemia, which must be corrected prior to initiation.

Contraindications and Safety Monitoring

Calcifar Plus is contraindicated in patients with conditions that prevent proper esophageal emptying (e.g., stricture, achalasia), uncorrected hypocalcemia, and in those unable to remain upright for a full 30 minutes after dosing. Hypersensitivity reactions, including urticaria and angioedema, have been reported in post-marketing experience.

Patients should be monitored for signs of upper GI irritation, mineral imbalances, and new or worsening bone pain, especially with prolonged use, to manage risks associated with the drug's components.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Calcifar Plus, a combination of calcium hydrogen phosphate and colecalciferol, is primarily defined by the development of hypercalcaemia and hypervitaminosis D. This condition is documented in regulatory labeling to produce a distinct set of clinical manifestations.

Documented Manifestations and Severe Outcomes

System Documented Signs/Symptoms
Gastrointestinal Anorexia, nausea, vomiting, constipation, and abdominal pain.
Systemic Muscle weakness, fatigue, excessive thirst (polydipsia), and frequent urination (polyuria).
Severe Outcomes Irreversible renal damage, cardiac arrhythmias, soft tissue calcification, and potential progression to coma in extreme cases.

Official Emergency Actions

The official prescribing information mandates specific actions when overdose is suspected. You must seek immediate medical attention and discontinue the supplement upon the onset of persistent gastrointestinal symptoms, mental disturbances (like confusion), or severe systemic signs.

Regulatory documentation states that no specific antidote is known. Management is defined as symptomatic and supportive, often requiring procedures like rehydration and continuous monitoring of serum calcium levels and renal function. Overdose leading to prolonged hypercalcaemia must be avoided during pregnancy due to documented adverse effects on the developing foetus.

Therapeutic Uses of Calcifar Plus

What Calcifar Plus Treats: Main Uses and Benefits

Calcifar Plus is considered relevant in therapeutic domains where additional supportive management is needed to address deficiencies in both calcium and Vitamin D. The primary therapeutic indications include the management and prevention of calcium deficiency (hypocalcemia) and Vitamin D deficiency. It is also applied to conditions where these deficiencies lead to structural compromise, such as osteoporosis, osteomalacia, and rickets in children.

This type of combination supplement is considered relevant within therapeutic areas involving existing osteoporosis management and for deficiency correction. The formulation addresses symptoms that interfere with daily comfort, such as chronic bone pain and generalized muscle weakness, especially in high-risk groups like older adults and postmenopausal women.

“This combination supports the body's efforts to help reduce the risk of structural compromise associated with chronic mineral deficiency.”

It assists with maintaining the body's mineral levels in situations where the body's nutrient needs are higher, and contributes to improved comfort during symptomatic periods.


Quick Fact: Relief for Musculoskeletal Discomfort
Supports the easing of muscle weakness and bone pain associated with mineral deficiency.

Eligibility and Restrictions for Use

This section outlines the eligibility criteria and formal contraindications for use, as defined in authoritative governmental regulatory documents. The use of this medicine is restricted to certain populations and prohibited for others based on specific pre-existing health conditions or physiological states.

Populations for Whom Use is Prohibited (Contraindications)

Individuals must not use this product if any of the following official contraindications are present:

  • A known hypersensitivity or allergy to any active or inactive component of the medicine.
  • Existing conditions of elevated calcium levels, specifically hypercalcemia (high calcium in the blood) or hypercalciuria (high calcium in the urine).
  • Excess levels of Vitamin D in the body, known as hypervitaminosis D.
  • A history of or current conditions that predispose a patient to forming renal calculi (kidney stones).

Restricted or Not Recommended Populations

Official labeling defines additional groups where the medicine is not recommended or requires special consideration:

  • Pediatric Use: The product is not indicated for use in children or adolescents.
  • Renal Function: Use is not recommended in patients with severe renal insufficiency (impaired kidney function). This restriction is often specified by a low creatinine clearance value (e.g., less than 35 mL/min).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for the combination of Calcium and Colecalciferol (Vitamin D3), based strictly on regulatory prescribing information.


Documented Interaction Patterns

Mechanism / Substance Category Official Interaction Pattern / Restriction
Chelation / Absorption Interference (Tetracyclines, Quinolones, Bisphosphonates, Levothyroxine, Iron) The calcium component significantly reduces the absorption of the co-administered drug, requiring mandatory time separation of two to six hours between doses.
Metabolic Enzyme Induction (Anticonvulsants, Rifampicin) May diminish the effect of the Colecalciferol component due to increased metabolic breakdown.
Excretion Modification (Thiazide Diuretics) Reduces the urinary excretion of calcium, leading to an increased risk of hypercalcaemia.
Additive Pharmacodynamic Risk (Cardiac Glycosides) Hypercalcaemia resulting from the combination may accentuate the risk of digitalis toxicity and serious arrhythmias.

Official Restrictions and Contraindications

Vitamin D Metabolites or Analogues (e.g., Calcitriol) are classified as contraindicated combinations due to the significant and additive risk of developing hypercalcaemia. Patients with impaired renal function face a higher risk of hypermagnesaemia when co-administered with magnesium-containing products. Additionally, the concurrent consumption of large amounts of milk or dairy products can contribute to the risk of Milk-Alkali Syndrome.

Mechanism of Action

Mechanism of Action: How Calcifar Plus Works

Calcium carbonate provides a direct mineral substrate, leading to deposition and incorporation into the bone matrix. Vitamin D3 facilitates this process by enhancing intestinal calcium absorption. Specifically, Vitamin D3 modulates the synthesis of calcium-binding proteins and induces the expression of the apical membrane Ca^2+ channel TRPV6 and the basolateral Ca^2+ pump PMCA1b in enterocytes. This specific molecular cascade increases transcellular calcium flux, resulting in an elevation of circulating serum calcium concentration.

Zinc acts as an essential cofactor for the enzyme alkaline phosphatase (ALP), which is critical for initiating bone mineralization and regulating bone remodeling dynamics. The combined presence of Vitamin D3 and Zinc modulates the spatial organization of the collagen matrix and hydroxyapatite crystal formation. The coordinated action of all ingredients ultimately influences the molecular and biomechanical properties of the skeletal structural matrix.

Dosage and Administration Information

How to Use Calcifar Plus: Administration Guidelines

Calcifar Plus, a combination of calcium salt and colecalciferol (Vitamin D3), is administered based on instructions defining the route, schedule, and specific conditions for intake.


Administration Scope

Property Instruction Detail
Route of administration Oral use only.
Dosing schedule Total daily intake is typically 1000 mg to 1200 mg of elemental calcium and 800 IU to 1000 IU of Vitamin D3. The regimen is usually one tablet daily or one tablet twice daily.
Timing in relation to meals May be taken with or without food.
Preparation requirements Chewable tablets must be chewed or sucked completely, not swallowed whole. Effervescent tablets must be fully dissolved in water.
Age-group rules The standard combination strengths are not intended for use in the paediatric population. Use in severe renal impairment is generally not permitted.
Special procedural conditions Requires temporal separation from certain co-administered medications, often a 2 hour gap before or a 4 to 6 hour gap after, to avoid absorption interference.

Official Use Protocol

The administration is intended for long-term use and continuation is subject to adjustment based on laboratory monitoring, such as measuring serum and urinary calcium levels. The dosage calculation must always account for calcium and Vitamin D3 intake from other sources to maintain proper levels. This structured approach ensures use aligns with established parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calcifar Plus

The evidence base for Calcifar Plus is derived from studies evaluating the combination of calcium hydrogen phosphate and colecalciferol. This research has primarily focused on the necessity of these components for skeletal health and maintaining proper mineral balance in the body.


Evidence for Management of Osteoporosis and Fracture Risk

This section will summarize the structure of the key research, including Randomized Controlled Trials (RCTs) and meta-analyses, that have evaluated the combination in the context of osteoporosis and its potential association with fracture occurrence in older adults.

Large-scale, controlled trials have explored the use of this combination in older adults and postmenopausal women by monitoring changes in bone health over time. Data from meta-analyses of these studies show patterns related to fracture occurrence, particularly in high-risk groups. However, results was observed in some studies to be less consistent when the research included a broad community-dwelling older adult population.

Primary Outcomes Measured in Osteoporosis Trials

In addition to tracking fracture events, researchers also monitored changes in Bone Mineral Density (BMD). The research examined how changes in BMD were associated with the use of the combination. Findings describe patterns observed in the studies where BMD measurements evolved in the observed populations, which contributes to the broader evidence landscape related to skeletal outcomes measured.


Evidence for Deficiency Correction and Treatment

Studies on Musculoskeletal Support and Function

Research has explored outcomes related to systemic or functional imbalance, such as muscle weakness and physical discomfort. This combination was evaluated in studies where muscle function was measured. However, evidence quality varies across studies that measured muscle strength.


What is Still Uncertain About Calcifar Plus Research

While a significant body of research exists, certain areas remain uncertain. Evidence quality varies across studies when the combination was evaluated in broad groups of older adults who are not confirmed to be deficient. Furthermore, there are discussions among scientific groups regarding the precise optimal serum level of vitamin D that constitutes sufficiency for all individuals. Data for certain groups remain insufficient and the long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Calcifar Plus (FAQ)


Q: Does Calcifar Plus cause weight gain?

A: Official product information does not list weight gain as a common or known side effect. Regulatory labeling indicates that unusual weight loss has been reported as a possible symptom related to high calcium levels (hypercalcemia), which can occur with excessive intake.


Q: Is it common to feel tired after starting Calcifar Plus?

A: Official documents state that feeling unusual tiredness or weakness has been reported as a side effect. This feeling has also been observed as a potential sign related to elevated calcium levels.


Q: Can I take Calcifar Plus with a vitamin supplement?

A: Regulatory documents indicate that the total daily dosage calculation should account for all calcium and Vitamin D3 intake from other sources, including supplements and diet. Concomitant use with other active Vitamin D forms, such as analogues or metabolites (e.g., Calcitriol), is officially contraindicated due to the high risk of elevated calcium levels.


Q: Can Calcifar Plus be crushed or split?

A: The official instructions state that the chewable tablet form must be completely chewed or sucked and not swallowed whole. For the standard Kaplet or tablet forms, there are typically no official instructions provided in regulatory documents that permit splitting or crushing.


Q: Are there any food or drinks I need to avoid while on Calcifar Plus?

A: Official regulatory warnings describe that taking Calcifar Plus with large amounts of milk or other dairy products can increase the risk of developing a condition called Milk-Alkali Syndrome. The labeling indicates that excessive intake of dairy products should be limited during use.


Q: Why is Calcifar Plus sometimes used for more than one condition?

A: The product’s intended use is related to the prevention and treatment of deficiencies in both calcium and Vitamin D. In addition to addressing deficiencies, studies summarized in the research evidence section have also specifically addressed its use in supporting bone health in conditions like osteoporosis and managing symptoms like muscle weakness.


Q: How often are the side effects of Calcifar Plus reported?

A: Official product labeling defines the most common adverse reactions as those observed in initial clinical trials involving three percent or more (≥ 3%) of participants. Other more severe adverse reactions are typically reported as rare events, often based on post-marketing experience rather than initial clinical trials.


Q: Can men and women use Calcifar Plus for the same reasons?

A: Yes, the official purpose of the medicine is to aid in the prevention and treatment of deficiencies in calcium and Vitamin D, which is an indication that applies to both men and women. While specific studies often focus on postmenopausal women regarding osteoporosis, the fundamental deficiency correction indication is gender-neutral.


Q: Can I take Calcifar Plus if I have a history of stomach ulcers?

A: Official safety information advises that caution is used if you have active upper gastrointestinal disease. While severe irritation is rare and can be minimized by correct use, the presence of conditions such as ulcers may require discussion with a healthcare provider regarding appropriate monitoring.


Q: What should I tell my pharmacist about before getting Calcifar Plus?

A: Official documents describe conditions and medications that are important to disclose to a healthcare provider before starting this product. These include any known hypersensitivity or allergy to the components, pre-existing conditions like high blood calcium (hypercalcemia) or kidney stones (renal calculi), and the use of specific interacting medications (like certain antibiotics, heart medicines, or diuretics).


Q: Are there any lifestyle changes recommended while taking Calcifar Plus?

A: Regulatory documents indicate that consumption of large amounts of milk or dairy products should be avoided to help mitigate safety risks. Furthermore, to support the effectiveness of the Vitamin D component, official information indicates that maintaining an adequate dietary calcium intake is necessary.


Q: What does the patient information leaflet say about stopping Calcifar Plus?

A: Official product information states that continued use is subject to adjustment based on laboratory monitoring, such as measuring calcium levels. The therapy may also need to be discontinued if serious adverse reactions, such as new or severe musculoskeletal pain, develop during use.


Q: Are there different formulations of Calcifar Plus (e.g., tablet, capsule, liquid)?

A: According to the official regulatory documents, the product is available in Oral dosage forms, which typically include a standard Kaplet or Tablet and a Chewable Tablet designed to be sucked or chewed. Other formats, such as capsules or liquid solutions, are not generally specified in the official product information.


Q: What should I do if I forget to take Calcifar Plus?

A: Official regulatory guidance suggests that if a dose is missed, it can be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped. The regular schedule should be resumed, and taking two doses simultaneously should be avoided.


Q: Is Calcifar Plus known to cause problems with sleep?

A: Official product safety information indicates that adverse reactions, such as insomnia or difficulty sleeping, have been reported for related Vitamin D compounds. If trouble sleeping occurs, it is recommended that this is discussed with a healthcare provider.


Q: Does Calcifar Plus have a black box warning?

A: According to the FDA regulatory label for these components, this product does not contain a Boxed Warning (often called a Black Box Warning). This type of warning is reserved for serious adverse effects and is not featured on the official labeling for the combination of calcium and Vitamin D3.


Q: What happens if I stop taking Calcifar Plus suddenly?

A: Official information indicates that stopping the treatment may lead to a decrease in calcium levels in the body, which could affect bone health and potentially cause deficiency symptoms to return. Any decision to stop or change treatment is typically made in consultation with a healthcare provider.


Q: Is Calcifar Plus a controlled substance?

A: Official regulatory bodies, such as the DEA, have not classified the components of Calcifar Plus (Calcium and Cholecalciferol) as controlled substances. This medicine is generally classified within the Multivitamins and Minerals pharmacological class.


Q: Does Calcifar Plus contain lactose or gluten?

A: While the active ingredients are specified, the inactive ingredients, such as lactose or gluten, can vary between commercial formulations and manufacturers. Because of this variation, the specific ingredient list printed on the official product labeling should be consulted for the presence of substances like lactose or gluten.


Q: What happens if I accidentally take two Calcifar Plus tablets at once?

A: If you accidentally take two tablets at once, official information indicates this is generally unlikely to cause serious harm unless it represents a significant overdose above your typical prescribed level. If two tablets are accidentally taken at once, patients should generally follow their prescribed dosing schedule afterward and not take two doses to make up for a missed dose.


Q: What is the regulatory status of Calcifar Plus (e.g., prescription or over-the-counter)?

A: The regulatory status can vary based on the dosage and country. In some regulatory systems, such as the US, many calcium and Vitamin D3 combinations are categorized as Human Over-The-Counter (OTC) Drugs. The specific classification (prescription or OTC) for a particular product and strength can be found in the official country-specific product information.


Q: Is there a link between Calcifar Plus and changes in mood?

A: Official safety documents note that mood changes or feelings of depression have been reported as possible adverse effects or symptoms related to hypercalcemia, which is a condition where calcium levels in the blood become too high.

How should Calcifar Plus be stored and disposed of?

How to Store and Dispose of Calcifar Plus

Official regulatory guidelines for this combination product (Calcium and Vitamin D3) define strict storage and disposal requirements.

Storage Requirements

The medication must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). It is mandatory to keep the container tightly closed and store it in a cool dry place to protect it from moisture. The product must not be frozen and must be protected from temperatures exceeding 40 C. For safety, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Calcifar Plus should not be disposed of in household wastewater (such as flushing down the toilet or pouring down a drain). Disposal must be accomplished through an official medicine take-back program or by following specific household disposal procedures mandated by local regulations for non-hazardous medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcifar Plus found in:

A-Z Index: